Release Date: 12-Jul-2024
Multiple myeloma emerges as a leading indication for bispecific antibodies, with approved therapies targeting BCMA and GPRC5D, two key antigens in disease pathogenesis. Clinical trials further underscore the significance of these antigens, with ongoing investigation into their therapeutic potential. However, the landscape is evolving with the development of new candidate targeting additional antigens such as CD38. This diversification offers a broader spectrum of therapeutic options, potentially addressing treatment resistance and improving patient outcomes. With continued research and innovation, bispecific antibodies hold promise in reshaping the treatment paradigm for multiple myeloma, offering renewed hope to patients facing this challenging hematological malignancy.
Download Report:
https://www.kuickresearch.com/report-bispecific-antibody-market-bispecific-antibodies-market